Bevacizumab Against Recurrent Retinal Detachment (BEARRD)

Active Clinical Trials // Feb 14 2017

sponsored by FA Davis

 

Principal Investigator: Michael Ip

Coordinators: Angie Adler and Kristine Dietzman

Purpose

To investigate if intravitreal bevacizumab injection during primary vitrectomy surgery can reduce recurrent RD and PVR.

Subjects are patients with a rhegmatogenous RD who are under the care of one of the ophthalmologists at University of Wisconsin Hospital and Clinics (UWHC).

The study population will consist of approximately 100 eyes of patients recruited by ophthalmologists at UWHC.

Inclusion criteria

o Age ≥ 18 years

o Eyes with rhegmatogenous retinal detachment

Exclusion criteria

o Presence of PVR

o Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.

o Recent intravitreal injection of an anti-VEGF agent less than 3 months prior

o Secondary retinal detachment repair

o Use of silicone oil as tamponade agent

o Patients less than 18 years of age

o Pregnancy

o Known previous adverse response or contraindication to intravitreal bevacizumab

o History of stroke or malignant hypertension in the previous 6 months

Please contact the study coordinator with questions: Angie Adler 608-265-7557